Secondary primary malignancies during the lenalidomide–dexamethasone regimen in relapsed/refractory multiple myeloma patients

Lenalidomide in combination with dexamethasone (Len‐dex) represents a highly effective treatment in relapsed/refractory multiple myeloma (RRMM) patients. However, an increased risk of secondary primary malignancies (SPMs), including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Kotchetkov, Rouslan, Masih‐Khan, Esther, Chu, Chia‐Min, Atenafu, Eshetu G., Chen, Christine, Kukreti, Vishal, Trudel, Suzanne, Tiedemann, Rodger, Reece, Donna E.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5269689/
https://ncbi.nlm.nih.gov/pubmed/27860411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.799
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados